2024-02-14 21:08:44
Image source: Getty Image Bank
[메디칼업저버 배다현 기자] Additional research results showed that phosphodiesterase 5 inhibitors (PDE5I), used to treat erectile dysfunction, lower the risk of Alzheimer’s disease.
A five-year follow-up study of men who were prescribed PDE5I to treat erectile dysfunction found that their risk of developing Alzheimer’s disease was 18% lower than those who were not prescribed PDE5I. The results of this study were announced in the online edition of Neurology on February 7.
The study looked at men aged 40 and older who were newly diagnosed with erectile dysfunction between 2000 and 2007, based on UK primary care data.
The study included 269,725 men, of whom 1,119 (55%) were prescribed a PDE5I. At the start of the study, the participants had no memory or cognitive problems.
As a result of the study, 749 patients prescribed PDE5I and 379 patients not prescribed PDE5I were diagnosed with Alzheimer’s disease. This corresponds to a rate of 8.1 and 9.7 people per 10,000 person-years, respectively.
Overall, patients prescribed PDE5I had an 18% lower risk of Alzheimer’s disease compared to patients not prescribed PDE5I (aHR 0.82; 95% CI 0.72-0.93). This association was stronger in patients over 70 years of age and with a history of high blood pressure or diabetes.
The risk reduction rate also differed depending on the number of PDE5I prescriptions.
Patients who received 21 to 50 prescriptions had a 44% lower risk of developing Alzheimer’s disease compared to patients who did not receive any prescriptions (aHR 0.56; 95% CI 0.43 to 0.73). Patients who received more than 50 prescriptions were found to have a 35% lower rate (aHR 0.65; 95% CI 0.49-=~0.87).
However, no evidence was found to reduce the risk of developing Alzheimer’s disease in patients who received fewer than 20 prescriptions.
A sub-analysis found evidence of a reduced risk of Alzheimer’s disease in patients prescribed Viagra (sildenafil) (aHR 0.81; 95% CI 0.71 to 0.93).
On the other hand, there was no evidence of reduced risk in patients who were prescribed Cialis (tadalafil) and Levitra (vardenafil) compared to patients who were not prescribed the drug.
Considering the latency period between the onset of Alzheimer’s disease and diagnosis, no evidence of risk reduction was found in subanalysis results with a 1-year and 3-year delay period following entering the cohort.
Controversy continues over conflicting research results…necessity of randomized controlled trials
Pfizer’s ‘Viagra (ingredient name: sildenafil)’
Controversy continues in the academic world as two previous studies investigating the association between PDE5I and the risk of Alzheimer’s disease produced conflicting results.
A study published in 2021 by a research team at the University of Cleveland found that Viagra and Cialis prevent Alzheimer’s disease and dementia by 69%.
However, a study by Professor Rishi Desai’s team at Brigham and Women’s Hospital published in 2022 concluded that PDE5I was not related to the prevention of Alzheimer’s disease and dementia.
Experts said that the results of this study are not evidence that PDE5I can treat Alzheimer’s disease, and caution is urged in interpreting the results.
Dr. Ruth Brauer of University College London, UK, who conducted the study, said, “To increase the generalizability of the study results, a randomized controlled trial is needed that includes both men and women and explores various doses,” and added, “Confirm the association between PDE5I and Alzheimer’s disease.” “It will be helpful,” he said.
1707947757
#erectile #dysfunction #drugs #risk #Alzheimers #disease #Present #additional #evidence
